SCHEMBL10305014

SCHEMBL10305014

COc1cccc(-c2cc(F)c(OC)cc2C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.39
BTK Q06187 1/20 0.38
HSP90AA1 P07900 3/20 0.38
HSP90AB1 P08238 2/20 0.38
TRAP1 Q12931 1/20 0.38
MAP4K1 Q92918 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NPC1 O15118 1/20 0.37
NFKB1 P19838 1/20 0.37
RAB9A P51151 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
APLNR P35414 5/20 0.37
NR4A2 P43354 1/20 0.37
DHODH Q02127 1/20 0.37
TGFBR1 P36897 1/20 0.36
HSD17B14 Q9BPX1 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305037 0.88 BTK (0.42) BTKHSP90AA1HSP90AB1ALDH1A1NPC1
SCHEMBL13745218 0.84 HSP90AA1 (0.39) BTKHSP90AA1HSP90AB1TRAP1MAP4K1
SCHEMBL10305104 0.79 CYP11B2 (0.46) HSP90AA1HSP90AB1
SCHEMBL10304943 0.79 ATR (0.42) BTKAPLNR
SCHEMBL10304939 0.79 PDE2A (0.47) BTKHSP90AA1HSP90AB1TRAP1
SCHEMBL9982240 0.79 ABL1 (0.51) BTKHSP90AA1HSP90AB1TRAP1
SCHEMBL9981152 0.75 OXTR (0.42) BTKHSP90AA1HSP90AB1TRAP1NR4A2
SCHEMBL10305012 0.75 HSP90AA1 (0.46) BTKHSP90AA1HSP90AB1ALDH1A1RAB9A
SCHEMBL10304967 0.74 HSP90AA1 (0.47) BTKHSP90AA1HSP90AB1ALDH1A1NPC1
SCHEMBL10304934 0.74 NNMT (0.44) BTKHSP90AA1HSP90AB1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 FFAR1 4808/4885BTK 509/4885HSP90AA1 2/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 FFAR1 4808/4885BTK 509/4885HSP90AA1 2/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 FFAR1 4808/4885BTK 509/4885HSP90AA1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.